{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:44:31Z","timestamp":1761709471607,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T00:00:00Z","timestamp":1518912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00198-018-4385-0","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T19:36:05Z","timestamp":1518896165000},"page":"999-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-461X","authenticated-orcid":false,"given":"N.","family":"Binkley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"de Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,18]]},"reference":[{"key":"4385_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2017-00096","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358","journal-title":"J Clin Endocrinol Metab"},{"key":"4385_CR2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics. Osteoporos Int 27:1917\u20131921","journal-title":"Osteoporos Int"},{"key":"4385_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296","journal-title":"J Bone Miner Res"},{"key":"4385_CR4","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925","journal-title":"Osteoporos Int"},{"key":"4385_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","volume":"54","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Terpos E (2016) Clinical vertebral fractures following denosumab discontinuation. Endocrine 54:271\u2013272","journal-title":"Endocrine"},{"key":"4385_CR6","doi-asserted-by":"publisher","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JEB, McClung M, Roux C, T\u00f6rring O, Valter I, Wang AT, Brown JP (2017) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. \n                    https:\/\/doi.org\/10.1002\/jbmr.3337","DOI":"10.1002\/jbmr.3337"},{"key":"4385_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"key":"4385_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394\u2013402","journal-title":"J Clin Endocrinol Metab"},{"key":"4385_CR9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"4385_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ar.a.10119","volume":"275","author":"HM Frost","year":"2003","unstructured":"Frost HM (2003) Bone\u2019s mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol 275:1081\u20131101","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"4385_CR11","doi-asserted-by":"publisher","first-page":"43399","DOI":"10.1038\/srep43399","volume":"7","author":"S Ma","year":"2017","unstructured":"Ma S, Goh EL, Jin A, Bhattacharya R, Boughton OR, Patel B, Karunaratne A, Vo NT, Atwood R, Cobb JP, Hansen U, Abel RL (2017) Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Sci Rep 7:43399","journal-title":"Sci Rep"},{"key":"4385_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","volume":"26","author":"HG Bone","year":"2015","unstructured":"Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A (2015) Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos Int 26:699\u2013712","journal-title":"Osteoporos Int"},{"key":"4385_CR13","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, le Bailly de Tilleghem C, DaSilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251\u20132258","journal-title":"J Bone Miner Res"},{"key":"4385_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242\u2013251","journal-title":"J Bone Miner Res"},{"key":"4385_CR15","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1210\/jc.2016-4037","volume":"102","author":"SD Rao","year":"2017","unstructured":"Rao SD, Qiu S, Dhaliwal R, Bhadada SK (2017) Letter to the editor: severe rebound-associated vertebral fractures after denosumab discontinuation. J Clin Endocrinol Metab 102:2111","journal-title":"J Clin Endocrinol Metab"},{"key":"4385_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jocd.2015.06.008","volume":"18","author":"BC Silva","year":"2015","unstructured":"Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie WD (2015) Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions part 2: trabecular bone score. J Clin Densitom 18:309\u2013330","journal-title":"J Clin Densitom"},{"key":"4385_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bone.2015.06.007","volume":"79","author":"C Muschitz","year":"2015","unstructured":"Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann P, Hans D, Muschitz GK, Fahrleitner-Pammer A, Resch H (2015) TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79:259\u2013266","journal-title":"Bone"},{"key":"4385_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/fampra\/cmw120","volume":"34","author":"BC Zwaard van der","year":"2017","unstructured":"van der Zwaard BC, van Hout W, Hugtenburg JG, van der Horst HE, Elders PJ (2017) Adherence and persistence of patients using oral bone sparing drugs in primary care. Fam Pract 34:525\u2013531","journal-title":"Fam Pract"},{"key":"4385_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","volume":"12","author":"A Fahrleitner-Pammer","year":"2017","unstructured":"Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12:58","journal-title":"Arch Osteoporos"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-4385-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T19:02:42Z","timestamp":1550430162000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-4385-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,18]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-4385-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2018,2,18]]},"assertion":[{"value":"20 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}